Biologic for Rare Form of Psoriasis Under FDA Priority Review Biologic for Rare Form of Psoriasis Under FDA Priority Review

The indication under review for spesolimab, an interleukin-36 receptor antagonist, is for the treatment of flares in patients with generalized pustular psoriasis.Medscape Medical News

Source: Medscape Dermatology Headlines - December 17, 2021 Category: Dermatology Tags: Dermatology News Source Type: news